Show simple item record

dc.contributor.advisorMeyer, Mervin
dc.contributor.authorMirfin, Tayla Michele
dc.date.accessioned2021-04-09T15:09:43Z
dc.date.available2021-04-09T15:09:43Z
dc.date.issued2020
dc.identifier.urihttp://hdl.handle.net/11394/8184
dc.description>Magister Scientiae - MScen_US
dc.description.abstractHuman Immunodeficiency Virus (HIV), which is the cause of Acquired Immunodefiency Syndrome (AIDS) is a major global public health issue affecting over 37 million people worldwide and is responsible for claiming over 32 million lives since the discovery of the disease in 1981. Through effective diagnosis, treatment and prevention HIV is a manageable disease. Today, advanced antiretrovirals, known as HAART, serve as effective, first-line drug regimens, consisting of a variety of viral inhibitors, and have successfully helped viral suppression. However, issues arise with antiretrovirals due to patient non-adherence and the development of drug resistant mutations. Coupled with dormant HIV reservoirs, viral extinction is attenuated. It is therefore essential that effective alternative treatments are investigated. The exploration of nanomedicine for targeted drug delivery has shown an ability to prolong the drug circulation time, target drugs to specific sites in the body, and enhance drug effectiveness. A previous study demonstrated a novel therapeutic strategy that was based on a mutant version of the caspase-3 enzyme that can induce apoptosis in HIV infected cells. This therapeutic strategy has the potential to wipe out reservoirs of HIV infection. However, the therapeutic strategy lacked selectivity because the delivery mechanism was based on protein transduction technology which will result in the nonselective delivery of the drug. In this study, preliminary work towards the development of a targeted nanoparticle delivery system for this mutant caspase-3 enzyme is described. The study describes the synthesis of green fluorescent protein loaded alginate/chitosan nanoparticles that were functionalized with a DNA aptamer intended to target the nanoparticles to CD4 expressing cells, that are also targeted by HIV. The THP-1 cell line was used due to the ability of the cells to express CD4 receptors on the cell surface. The nanoparticles were synthesized through ionotropic gelation. The size, polydispersity, zeta potential and morphology were investigated by Dynamic Light Scattering and Scanning Electron Microscopy, respectively. The strongly negative zeta potential studies revealed stability of the nanoparticles in suspension and Scanning Electron Microscopy results showed an indicative collapse of the polymer network for the empty nanoparticles (i.e. nanoparticles not loaded with GFP), whereas solid, cuboid nanoparticles were shown for the GFP-loaded nanoparticles. Image-based fluorescence cytometry demonstrated that the GFP-loaded nanoparticles bind to the THP-1 cells that express the CD4 receptor. The results obtained are indicative of a potential drug delivery system for HIV treatment however, adjustments would need to be made to the current study to further develop this nanocarrier.en_US
dc.language.isoenen_US
dc.publisherUniversity of the Western Capeen_US
dc.subjectAptamersen_US
dc.subjectAlginateen_US
dc.subjectChitosanen_US
dc.subjectCD4en_US
dc.subjectElectrostatic complexationen_US
dc.subjectHIVen_US
dc.subjectLonotropic gelationen_US
dc.subjectPolymeric nanoparticlesen_US
dc.subjectNanomedicineen_US
dc.titleTargeted delivery of GFP loaded polymeric nanoparticles to CD4 expressing cells using a CD4 specific aptameren_US
dc.rights.holderUniversity of the Western Capeen_US


Files in this item

Thumbnail

This item appears in the following Collection(s)

Show simple item record